Concepedia

Mpumi Maxebengula

MM

Statistics

Publications

4

Citations

119

H-Index

4

Active since

2021

Affiliations

University of Cape Town(Current)

University College London

Imperial College London

Wellcome Centre for Infectious Diseases Research in Africa

The Francis Crick Institute

Mpumi Maxebengula is an author at University of Cape Town specializing in antimicrobial pharmacotherapy, rifampicin therapy, and clinical pharmacology.

Publications per year

2021–2022

4

Publications

4

A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated Tuberculous Meningitis: The LASER-TBM Trial

Angharad Davis, Sean Wasserman, Cari Stek et al. · Clinical Infectious Diseases · 2022 · 43 citations · Full text

, , +14

Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial

Sean Wasserman, Angharad Davis, Cari Stek et al. · Antimicrobial Agents and Chemotherapy · 2021 · 40 citations · Full text

, , +14

Cognitive Impairment in Tuberculous Meningitis

Angharad Davis, Anna J. Dreyer, Christine Albertyn et al. · Clinical Infectious Diseases · 2022 · 23 citations · Full text

, , +16

Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]

Angharad Davis, Sean Wasserman, Mpumi Maxebengula et al. · Wellcome Open Research · 2021 · 13 citations · Full text

, , +14

1–4 of 4